Christi Shaw - 12 Jan 2026 Form 4 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Reporting relationship: Executive Chairperson, Director
Issuer ticker: KYTX
Reported as of: 12 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Jan 2026, 17:00:10 UTC
Prior SEC filing: 06 Jun 2025
Next SEC filing: 29 May 2026
Source filing: View source filing
Reporting owner signature: By: /s/ Samantha Eldredge, as Attorney-in-Fact

Key filing fact

Christi Shaw filed Form 4 for Kyverna Therapeutics, Inc. (KYTX) on 14 Jan 2026.

Key facts

This page summarizes Christi Shaw's Form 4 filing for Kyverna Therapeutics, Inc. (KYTX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 14 Jan 2026, 17:00.

Change

Previous filing in this sequence was filed on 06 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001702473 Primary reporting owner

Shaw Christi

Relationship: Executive Chairperson, Director
Address: C/O KYVERNA THERAPEUTICS, INC., 5980 HORTON ST., STE 550, EMERYVILLE
Signature: By: /s/ Samantha Eldredge, as Attorney-in-Fact
Signature date: 14 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KYTX transaction

Common Stock

Award

Transaction value: $0
Shares: +30,000
Change %: +180%
Price: $0.000000
Shares after: 46,634
Date: 12 Jan 2026
Ownership: Direct
Footnotes: F1

KYTX transaction

Common Stock

Award

Transaction value: $0
Shares: +24,301
Change %: +52%
Price: $0.000000
Shares after: 70,935
Date: 12 Jan 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KYTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +185,000
Change %
Price: $0.000000
Shares after: 185,000
Date: 12 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 185,000
Exercise price: $8.23
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents a restricted stock unit award of common stock, 1/4th of the shares subject to which shall vest on January 12, 2027, and 1/4th of the shares subject to the restricted stock unit award shall vest following each one-year period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Footnote F2

Represents a performance restricted stock unit award of common stock, which will vest upon the Issuer's common stock achieving certain specified prices per share.

Footnote F3

1/4th of the shares subject to the option shall vest on January 12, 2027, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.